Status:
RECRUITING
Role of the Fibroblast Activation Protein (FAP) as Biomarker of Fibrotic Lung Diseases
Lead Sponsor:
Erasme University Hospital
Conditions:
Pulmonary Fibrosis
Lung Fibrosis
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
To evaluate the effect of an anti-fibrotic treatment initiation on the fibrotic activity as assessed by FAPI PET/CT.
Detailed Description
To evaluate the use of the fibroblast activation protein (FAP) as a biomarker of fibrotic lung disease (idiopathic pulmonary fibrosis (IPF) and non-IPF ILDs). The study will include both analysis of F...
Eligibility Criteria
Inclusion
- Adults patients with a fibrotic lung disease (idiopathic pulmonary fibrosis (IPF) or non-IPF fibrotic ILD) as defined according to the 2022 ATS/ERS/JRS/ALAT Clinical Practice Guidelines
Exclusion
- Pregnant or nursing patients
- Patients with another significant medical condition which, in the investigator's opinion, may interfere with the completion of the study.
- Patients with an active lung neoplasm or any active neoplasm for blood samples
Key Trial Info
Start Date :
March 9 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 9 2027
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT06189820
Start Date
March 9 2023
End Date
March 9 2027
Last Update
January 5 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medecine
Brussels, Belgium, 1070